Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

Austin T. Klein; Marc L. Mendillo

doi:10.1016/j.chembiol.2023.10.007

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

Austin T. Klein, Marc L. Mendillo^*

^*Corresponding author for this work

Biochemistry and Molecular Genetics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.¹ demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.

Original language	English (US)
Pages (from-to)	1334-1336
Number of pages	3
Journal	Cell Chemical Biology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1016/j.chembiol.2023.10.007
State	Published - Nov 16 2023

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmacology
Drug Discovery
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chembiol.2023.10.007

Cite this

@article{eb5637ee4fb6403d8f80ea90415812f8,

title = "Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors",

abstract = "The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.",

author = "Klein, {Austin T.} and Mendillo, {Marc L.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = nov,

day = "16",

doi = "10.1016/j.chembiol.2023.10.007",

language = "English (US)",

volume = "30",

pages = "1334--1336",

journal = "Cell Chemical Biology",

issn = "2451-9456",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Addicted to proteostasis

T2 - How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

AU - Klein, Austin T.

AU - Mendillo, Marc L.

PY - 2023/11/16

Y1 - 2023/11/16

N2 - The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.

AB - The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=85176344557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176344557&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2023.10.007

DO - 10.1016/j.chembiol.2023.10.007

M3 - Comment/debate

C2 - 37977128

AN - SCOPUS:85176344557

SN - 2451-9456

VL - 30

SP - 1334

EP - 1336

JO - Cell Chemical Biology

JF - Cell Chemical Biology

IS - 11

ER -

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this